Enflonsia Receives FDA Approval

Merck’s RSV Preventative ENFLONSIA Receives FDA Approval

ENFLONSIA is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

This new RSV prevention strategy will give pediatricians an additional option to the currently available product nirsevimab-alip made by Sanofi & AstraZeneca also known as BEYFORTUS™.

Considering respiratory syncytial virus is the leading cause of infant hospitalization in the United States, more options for prevention is welcome news.  Merck’s new product is also known as clesrovimab-cfor.  Both infant RSV prevention strategies ( ENFLONSIA & BEYFORTUS)  have shown impressive efficacy results.  Please see prescribing information for references to these clinical studies. Click here for more information on Merck’s ENFLONSIA.

Medical Practices needing access to discount pricing on these products made by Merck or Sanofi may do so through a free membership in the Physicians’ Buying Group (PBG) PracticeWell. 

‍